Intellia Therapeutics has initiated a rolling biologics license application (BLA) with the U.S. Food and Drug Administration for lonvoguran ziclumeran...
One or two years ago, if you had proposed lipid nanoparticles (LNPs) as an RNA delivery system for muscle diseases, you would likely have been met...
Engineered virus-like particles (eVLPs) are emerging as a distinct delivery platform for CRISPR-Cas ribonucleoprotein (RNP) complexes, combining the...
The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...
On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
iECURE's ECUR-506 has secured both the US FDA Regenerative Medicine Advanced Therapy designation and a UK Innovation Passport, positioning the...
Researchers at the University of Tokyo have developed a streamlined CRISPR-Cas9-based method that enables efficient replacement of entire mouse gene...
A first-in-human, phase I trial tested intrathecal delivery of CRISPR-Cas9-edited, allogeneic IL-13Rα2 CAR-T cells in five people with recurrent...
